ReviewBiomolecules2026
Biomarkers of Coagulation Disorders-Where to from Here?
Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Assessment of Hypercoagulability After Orthopedic Trauma Surgery Using Coagulation Biomarkers and TEG/ROTEM.International journal of molecular sciences · 2026Review
- Thromboinflammatory biomarkers and thrombotic risk in virologic failure and drug-resistant HIV: Emerging roles of d-dimer, fibrinogen, and coagulation dysregulation.Journal of thrombosis and thrombolysis · 2026Review
- Heparin Anticoagulant Therapy and Its Monitoring.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disorders of thrombosis and bleeding contribute to a significant morbidity and mortality burden worldwide. Correctly identifying contributing factors towards either thrombosis or bleeding carries implications for diagnosis, prognosis and management. Although there are established and commonly used biomarkers for both circumstances, the complexity of hemostasis contributes to the wide variability in assay methodology and information provided by each individual assay. There are several emerging biomarkers of thrombosis and hemostasis, which require further evaluation of their roles in diagnosis and management in specific patient populations. This narrative review summarizes established, emerging, and exploratory biomarkers of both thrombosis and bleeding disorders, outlining their biological roles, diagnostic utility, and limitations, with a particular focus on clinical relevance, assay methodology and future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.